Ventyx Biosciences, Inc. (NASDAQ:VTYX – Get Rating) hit a new 52-week high during mid-day trading on Friday . The company traded as high as $44.30 and last traded at $44.30, with a volume of 4297 shares changing hands. The stock had previously closed at $43.13.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. Evercore ISI boosted their price objective on shares of Ventyx Biosciences from $50.00 to $65.00 in a research report on Thursday, January 26th. Canaccord Genuity Group increased their price objective on shares of Ventyx Biosciences from $35.00 to $54.00 and gave the stock a "buy" rating in a research note on Tuesday, January 31st. Morgan Stanley started coverage on shares of Ventyx Biosciences in a report on Thursday, November 17th. They issued an "overweight" rating and a $45.00 target price for the company. The Goldman Sachs Group started coverage on shares of Ventyx Biosciences in a report on Monday, December 19th. They issued a "buy" rating and a $50.00 price objective for the company. Finally, Oppenheimer raised their price target on shares of Ventyx Biosciences from $55.00 to $60.00 and gave the stock an "outperform" rating in a report on Friday, January 27th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $52.78.

Ventyx Biosciences Trading Up 1.8 %

The firm has a fifty day moving average price of $33.07 and a two-hundred day moving average price of $28.57.

Insiders Place Their Bets

In other Ventyx Biosciences news, CEO Raju Mohan sold 276,997 shares of the company's stock in a transaction on Friday, December 2nd. The stock was sold at an average price of $29.01, for a total value of $8,035,682.97. Following the transaction, the chief executive officer now owns 1,564,814 shares of the company's stock, valued at approximately $45,395,254.14. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Ventyx Biosciences news, CEO Raju Mohan sold 276,997 shares of the stock in a transaction dated Friday, December 2nd. The stock was sold at an average price of $29.01, for a total value of $8,035,682.97. Following the completion of the sale, the chief executive officer now directly owns 1,564,814 shares in the company, valued at $45,395,254.14. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director William Richard White sold 33,353 shares of the stock in a transaction dated Monday, January 23rd. The shares were sold at an average price of $35.10, for a total value of $1,170,690.30. The disclosure for this sale can be found here. Insiders have sold a total of 1,206,646 shares of company stock valued at $36,781,043 in the last quarter. 49.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Ventyx Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in VTYX. Birchview Capital LP grew its stake in shares of Ventyx Biosciences by 36.4% in the third quarter. Birchview Capital LP now owns 45,000 shares of the company's stock valued at $1,571,000 after buying an additional 12,000 shares in the last quarter. Nantahala Capital Management LLC purchased a new stake in Ventyx Biosciences during the 3rd quarter worth about $4,072,000. TD Asset Management Inc. purchased a new stake in Ventyx Biosciences during the 3rd quarter worth about $570,000. The Manufacturers Life Insurance Company purchased a new stake in Ventyx Biosciences during the 3rd quarter worth about $980,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Ventyx Biosciences in the 3rd quarter valued at about $132,000. Hedge funds and other institutional investors own 95.57% of the company's stock.

Ventyx Biosciences Company Profile

(Get Rating)

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Its lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.

See Also

• Get a free copy of the StockNews.com research report on Ventyx Biosciences (VTYX)
• MarketBeat Week in Review – 1/30 – 2/3
• Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
• Zimmer Biomet Beats on Earnings, Growth May be Priced In
• AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
• Ford Stock Going Forward After Big Earnings Flop

Receive News & Ratings for Ventyx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventyx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.